Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibit...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/22/16109 |
| _version_ | 1797459095235592192 |
|---|---|
| author | Catherine C. Fahey Caroline A. Nebhan Sally York Nancy B. Davis Paula J. Hurley Jennifer B. Gordetsky Kerry R. Schaffer |
| author_facet | Catherine C. Fahey Caroline A. Nebhan Sally York Nancy B. Davis Paula J. Hurley Jennifer B. Gordetsky Kerry R. Schaffer |
| author_sort | Catherine C. Fahey |
| collection | DOAJ |
| description | Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV). EV was selected due to the evidence of the high expression of Nectin-4 in squamous cell carcinomas, including penile carcinoma. The patient had both radiographic and symptomatic improvement after two cycles of treatment, despite having been treated with multiple prior lines of traditional chemotherapy. This case provides support for the use of antibody–drug conjugates (ADC), including EV, in this disease with few other options in the advanced setting. Further studies examining Nectin-4 and ADCs in penile squamous cell carcinoma should be completed, as high-quality evidence is needed to guide treatment after initial progression for these patients. |
| first_indexed | 2024-03-09T16:46:31Z |
| format | Article |
| id | doaj.art-fb14be73bfc64840a4529b243d029d19 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T16:46:31Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-fb14be73bfc64840a4529b243d029d192023-11-24T14:46:02ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-11-0124221610910.3390/ijms242216109Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab VedotinCatherine C. Fahey0Caroline A. Nebhan1Sally York2Nancy B. Davis3Paula J. Hurley4Jennifer B. Gordetsky5Kerry R. Schaffer6Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USAIntermountain Health, Murry, UT 84107, USADepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USADepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USADepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USAVanderbilt-Ingram Cancer Center, Nashville, TN 37232, USADepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USAPenile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV). EV was selected due to the evidence of the high expression of Nectin-4 in squamous cell carcinomas, including penile carcinoma. The patient had both radiographic and symptomatic improvement after two cycles of treatment, despite having been treated with multiple prior lines of traditional chemotherapy. This case provides support for the use of antibody–drug conjugates (ADC), including EV, in this disease with few other options in the advanced setting. Further studies examining Nectin-4 and ADCs in penile squamous cell carcinoma should be completed, as high-quality evidence is needed to guide treatment after initial progression for these patients.https://www.mdpi.com/1422-0067/24/22/16109penile squamous cell carcinomaNectin-4antibody-drug conjugatetargeted therapymetastatic penile cancer |
| spellingShingle | Catherine C. Fahey Caroline A. Nebhan Sally York Nancy B. Davis Paula J. Hurley Jennifer B. Gordetsky Kerry R. Schaffer Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin International Journal of Molecular Sciences penile squamous cell carcinoma Nectin-4 antibody-drug conjugate targeted therapy metastatic penile cancer |
| title | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
| title_full | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
| title_fullStr | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
| title_full_unstemmed | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
| title_short | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
| title_sort | metastatic penile squamous cell carcinoma responsive to enfortumab vedotin |
| topic | penile squamous cell carcinoma Nectin-4 antibody-drug conjugate targeted therapy metastatic penile cancer |
| url | https://www.mdpi.com/1422-0067/24/22/16109 |
| work_keys_str_mv | AT catherinecfahey metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT carolineanebhan metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT sallyyork metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT nancybdavis metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT paulajhurley metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT jenniferbgordetsky metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT kerryrschaffer metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin |